Computerized Cognitive Training in Patients With Coronary Heart Disease and Mild Cognitive Impairment

Mild Cognitive Impairment Clinical Trial

— COG-T CHD  

Official title:

The Efficacy of Computerized Cognitive Training in Patients With Coronary Heart Disease and Cognitive Impairment, no Dementia: a Randomized Controlled Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05735041
• Other study ID #: 2022BFAZ02
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 18, 2023
• Est. completion date: July 31, 2025

Study information

• Verified date: February 2024
• Source: Beijing Anzhen Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, a multicentre, double-blind, randomized controlled study based on cognitive training was conducted in patients with coronary heart disease and cognitive impairment but without dementia， to evaluate the effectiveness of computer-based digital therapy in improving the cognitive function of such patients.

Description:

This study is a multicentre, double-blind, parallel randomized controlled study using a 1:1 parallel control design. A total of 200 patients with coronary heart disease combined with cognitive decline but no dementia were enrolled in 8 centres. These patients will be randomized to two arms under masking. The intervention arm will receive multi-domain adaptive cognitive training using a tablet. The control arm will receive an active control treatment and use the same tablet to receive the cognitive training tasks with weak difficulty change. Both arms will receive the same intervention dosage for 12 weeks, 5 times a week, and 30 minutes per time. After the 12-week intervention, the intervention arm will be re-randomized into two groups. One group will stop their intervention at 12 weeks; the other group will continue to receive the multi-domain adaptive cognitive training till the 24-week follow-up assessment. The neuro-psychological assessment will be administered at baseline, 12-week, and 24-week assessments for all participants. The structural and functional MRI will be administered at baseline, 12 weeks, and 24 weeks to evaluate the effect of cognitive training on brain structure and function.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 224
• Est. completion date: July 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

1. Over the age of 50;

2. Completion of more than 6 years of education;

3. Patients with coronary artery disease confirmed by coronary CT angiography or coronary angiography;

4. Chief complaint of cognitive decline within 1 year;

5. The average score of any cognitive domain in processing speed, situational memory, working memory and visual space measured by the Basic Cognitive Ability Test (BCAT) is less than 1 SD compared with the normal population;

6. Agree to be randomized to cognitive function tests and cognitive training and be able to receive follow-up as required.

Exclusion Criteria:

1. Previous definite diagnosis of dementia or brief Mental State Examination Scale (MMSE) < 24 points;

2. Cognitive dysfunction caused by cranial trauma, cranial tumor, Parkinson's disease, schizophrenia, Alzheimer's disease, anxiety and depression, and other neuropsychiatric diseases;

3. Deaf and mute or other reasons cannot communicate normally;

4. Binge drinking or taking drugs (antihistamines, antipsychotics) that affect cognitive function;

5. Unable to master the use of cognitive training equipment after two 1-hour training instructions each time;

6. Patients who plan to undergo coronary intervention within 6 months or have undergone coronary intervention within 1 month;

7. Severe liver and kidney function injury or critical condition, poor prognosis, estimated survival of less than 1 month.

8. Patients who had received general anesthesia within 3 months;

9. History of stroke and craniocerebral trauma within 6 months;

10. History of Parkinson's disease, schizophrenia, and epilepsy;

11. Prior neurosurgery or history of cranial tumors;

12. Nuclear magnetic examination contraindications: such as metal implants, claustrophobia, etc.;

13. patients living alone;

14. Patients with atrial fibrillation, structural heart disease, and infective endocarditis.

Related Conditions & MeSH terms

• Cognitive Dysfunction
• Coronary Artery Disease
• Coronary Disease
• Coronary Heart Disease
• Heart Diseases
• Mild Cognitive Impairment
• Myocardial Ischemia

Intervention

Behavioral:
• Multi-domain cognitive digital therapy
Patients in the cognitive digital therapy group received multi-dimensional targeted cognitive function training electronically, involving attention, memory, executive function, thinking, processing speed and perception. The system will adjust the training difficulty and training plan adaptively according to the patient's current training time and performance, and train the patient's weak cognitive ability as far as possible. The patients had the same total amount of training each day.
• Basic cognitive therapy
The training content of the positive control group was cognitive training tasks with weak difficulty or no difficulty change. The patients underwent cognitive function training with fixed programs, including 15 training items, and the internal difficulty of the training items remained constant without change. The system presents the training content randomly according to the training scheme. The patients had the same total amount of training each day.

Locations

Country	Name	City	State
China	Beijing Anzhen Hospital	Beijing
China	Beijing Sixth Hospital	Beijing
China	Peking University Third Hospital	Beijing
China	The second hospital of Chifeng	Chifeng
China	Handan Central Hospital	Handan
China	Inner Mongolia Ordos Central Hospital Kangbashi Department	Ordos
China	The First Affiliated Hospital of Hebei North University	Shijiazhuang
China	The First Hospital of Hebei Medical University	Zhangjiakou

Sponsors (2)

Lead Sponsor	Collaborator
Beijing Anzhen Hospital	Beijing Wispirit Technology Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Global cognitive function change measured by BCAT in 12 weeks	The proportion of patients whose global cognitive function improves 0.67SD compared to the baseline cognitive function measured by Basic Cognitive Ability test (BCAT). BCAT is a set of neuropsychological battery tests which was designed to measure global cognitive fucntion and cognitive function of sub-domains. Higher scores of BCAT means a better global cognitive function.	12 weeks after randomization
Secondary	Global cognitive function change measured by BCAT in 24 weeks	The proportion of patients whose global cognitive function improves 0.67SD compared to the baseline cognitive function at 24 weeks measured by Basic cognitive Ability Test(BCAT).	24 weeks after randomization
Secondary	Sub-domain cognitive function improvement including memory, attention, and execution memory	The proportion of patients whose sub-domain cognitive function, including attention, memory, execution function improves measured by the individual capability test in BCAT.	12 weeks, 24 weeks after randomization
Secondary	Cognitive score change	Mean change from baseline in global cognitive function score measured by basic cognitive ability test (BCAT) at 12 weeks and 24 weeks.	12 weeks, 24 weeks after randomization
Secondary	Self-efficacy score	Mean change from baseline in self-efficacy score measured by the General Self-Efficacy Scale at 12 weeks, and 24 weeks	12 weeks, 24 weeks after randomization
Secondary	Quality of life score	Mean change from baseline in the patient's quality of life score measured by EQ-5D-3L at 12 weeks and 24 weeks.	12 weeks, 24 weeks after randomization
Secondary	Anxiety score	Mean change from baseline in the patient's anxiety score at 12 weeks and 24 weeks. Anxiety status will be measured by GAD-7 questionnaire. Higher score of GAD-7 scale represents more anxiety status.	12 weeks, 24 weeks after randomization
Secondary	Depression score	Mean change from baseline in the patient's depression score at 12 weeks and 24 weeks. Depression status will be measured by PHQ-9 questionnaire. Higher score of PHQ-9 scale represents more depression status.	12 weeks, 24 weeks after randomization